Kyverna Therapeutics, Inc. KYTX Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Kyverna Therapeutics, Inc.’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s net proceeds from sales of subsidiary shares?
- Kyverna Therapeutics, Inc. (KYTX) reported net proceeds from sales of subsidiary shares of $98.97M in Q4 2025.
- What does net proceeds from sales of subsidiary shares mean?
- This represents the total cash proceeds received by the company from its initial public offering of equity securities, net of underwriting discounts and commissions. It serves as a primary source of capital for funding research, development, and general corporate purposes. This metric is a key indicator of the company's ability to access public capital markets to support its long-term growth strategy.